by Madaline Spencer | Feb 4, 2025
Carolina Schinke, MD, University of Arkansas for Medical Sciences, discusses differences in clinical outcomes of black patients with multiple myeloma treated with talquetamab. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by...
by Madaline Spencer | Feb 3, 2025
Christopher Patriquin, MD, University of Toronto, discusses results of a clinical trial comparing combination C5 inhibitor therapy versus standard of care in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare clonal hematopoietic stem...
by Madaline Spencer | Jan 30, 2025
Elias Mai, MD, Heidelberg Myeloma Center, discusses the GMMG-HD7 clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic...
by Madaline Spencer | Jan 28, 2025
Pieter Sonneveld, MD, Erasmus MC Cancer Institute, discusses results from the PERSEUS clinical trial for patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal...
by Madaline Spencer | Jan 27, 2025
Elias Jabbour, MD, MD Anderson Cancer Center, University of Texas, discusses results of a clinical trial evaluating bleximenib for patients with acute leukemia. Acute myeloid leukemias are a group of neoplasms arising from precursor cells committed to...
